Introduction
NSCLC, tumor, non-small-cell lung cancer
TUMOR, RECURRENCE, NSCLC
Effective therapies are urgently required for early-stage non-small-cell lung cancer (NSCLC) patients. The cornerstone treatment for early-stage NSCLC is supposed to be surgery. However more than half of the patients experienced recurrence after the complete resection alone.The identification of oncogenic driver mutations and development of tyrosine kinase inhibitors (TKIs) have dramatically reinvented the management of advanced NSCLC. This innovative treatment concept as “individualized therapy” has continued to step into the perioperative setting. Matched targeted treatments have become optimal options in the perioperative setting for resectable NSCLC with oncogenic driver mutations.Although neoadjuvant nivolumab plus chemotherapy has already obtained the approval of the U.S. Food and Drug Administration for NSCLC treatment,In the current prospective, multicenter, phase II study, we examine the safety and efficacy of neoadjuvant nivolumab, with or without platinum-doublet chemotherapy, according to PD-L1 expression levels at the tumor baseline. We also profile the ctDNA status at post-surgery as well as pre-neoadjuvant and post-neoadjuvant treatment time points, then discuss the relationship between ctDNA dynamics and pathological responses and survival outcomes.